CYP2D6 phenotyping in clinical practice: serum or urine dextromethorphan/dextrorphan metabolic ratio?
| Authors | |
|---|---|
| Year of publication | 2011 |
| Type | Article in Proceedings |
| Conference | 17th International Conference on Cytochrome P450 |
| MU Faculty or unit | |
| Citation | |
| Field | Pharmacology and pharmaceutical chemistry |
| Keywords | CYP2D6; phenotype |
| Description | The aim of this work was to elucidate if CYP2D6 phenotyping by evaluation of molar dextromethorphan to dextrorphan metabolic ratio (MRDEM/DOR) in serum has the usability and reliability as the assessment of MRDEM/DOR in urine. We measured MRDEM/DOR in serum and CYP2D6 genotype in 51 drug-naive patients and investigated cut-off value for discrimination of poor metabolizers from extensive and intermediate ones. The correlation of serum MRDEM/DOR with urine MRDEM/DOR in 30 healthy volunteers was analysed in parallel. |
| Related projects: |